- This event has passed.
EuropaBio Webinar – How will the revision EU General Pharmaceutical Legislation impact Europe’s innovation ecosystem and biotechnology companies?
7 March @ 1:00 pm – 2:30 pm CET
Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies.
Following the publication on 24 January 2024 of a new study analysing the expected impact of the GPL on the biotechnology innovation ecosystem, EuropaBio is delighted to invite you to attend its exclusive webinar to discuss the consequences of this landmark legislation for the future of innovation in healthcare in Europe, EU patients and economies within a global race towards health security and competitiveness.
The event will start with a presentation of the study by Charles Rivers Associates and will be followed by a panel discussion featuring leading voices of the European biotechnology ecosystem to discuss the impact of the proposed legislation and its consequences on the development of breakthrough medicines for EU patients.
The webinar will take place on Thursday 7 March at 13.00 CET. If you wish to attend, please register below.
Agenda:
- Welcome & Introduction: 13:00 – 13:05, Dr Claire Skentelbery, Director General EuropaBio
- Report Presentation and Q&A: 13:05 – 13:30, Antun Sablek & Tim Wilsdon, Charles River Associates
- Panel Discussion and Q&A: 13:30 – 14:25, Panelists: John James Ricketts, Noel Minnis, Thomas Bols, Tineke Van hooland, Wojciech Nowak and Yordan Aleksandrov. Moderated by Dr Claire Skentelbery.
- Concluding Remarks: 14:25 – 14:30 Dr Claire Skentelbery, Director General EuropaBio
Speakers: Moderated by Dr Claire Skentelbery, EuropaBio
- Antun Sablek, Charles River Associates
- John James Ricketts, Eli Lilly
- Noel Minnis, Takeda
- Thomas Bols, PTC Therapeutics
- Tim Wilsdon, Charles River Associates
- Tineke Van hooland, Bio.be
- Wojciech Nowak, Novartis
- Yordan Aleksandrov, Pfizer